Market Overview –
The Acute Pancreatitis Market Size was estimated to be worth USD 5.5 billion in 2022 and is expected to increase at a compound yearly growth rate (CAGR) of 5.90% from USD 5.8 billion in 2023 to USD 8.2 billion by 2030.
The acute pancreatitis market focuses on treatments and therapies for acute inflammation of the pancreas, a condition known as acute pancreatitis. This medical emergency can be caused by various factors such as gallstones, alcohol consumption, certain medications, infections, or trauma.
The acute pancreatitis market has seen growth due to the rising incidence of pancreatitis worldwide and advancements in treatment options. Key players include pharmaceutical companies developing medications to manage symptoms, medical device manufacturers producing endoscopic tools for intervention, and healthcare providers offering supportive care and surgical interventions.
The Acute Pancreatitis market is evolving, influenced by the increasing prevalence of pancreas diseases and growing awareness of associated symptoms. Symptoms of pancreas diseases like severe abdominal pain, nausea, and vomiting drive patient demand for effective treatments. This market's trajectory is shaped by advancements in diagnostic techniques and therapeutic interventions aimed at managing acute pancreatitis and improving patient outcomes.
Top Boosters and Deterrents –
The prevalence of acute pancreatitis across the globe has increased notably in the past few years, in line with the growing gallstone and obesity cases. The World Health Organization reveals that the global prominence of obesity almost tripled from 1975 to 2016, while acute pancreatitis cases were recorded in 17 nations in Europe, ranging from 4.6 to 100 per 100 000 individuals. The highest number of cases was reported in northern and Eastern Europe. Excessive alcohol consumption, significant cases of gallstones and ingested medicines are cited to be the top reasons for the increasing prevalence of acute pancreatitis around the globe.
Rising diagnostics rate combined with the increasing government support also largely also foster market growth. Moreover, advancements in biotechnological and pharmaceuticals industries have been favorable for the global industry as well. Intense efforts by researchers to develop effective drugs for the treatment of acute pancreatitis and the increasing funds being granted by authorities in this regard can also benefit the global market in the years to follow.
Renowned players are highly focused on new product launches and are increasingly boosting their global presence by gaining entry into untapped markets. Various firms are coming together to form alliance, with the prime focus on conducting research based on the treatment of acute pancreatitis. For instance, in June 2020, Mission Cure Holdings LLC came together with Ariel Precision Medicine Inc. and Path BioAnalytics Inc. to create a research-based alliance to come up with innovative and advanced treatments for acute pancreatitis. The collaboration between the three firms will enable them to facilitate a common objective, which is developing an effective and safe treatment option for the disease.
Market Segmentation
Acute Pancreatitis market has been carefully studied by MRFR based on segments such as cause, treatment & diagnosis and end user.
Depending on cause, the global market caters to alcohol, gallstones, and more. Gallstones own a share of 49.52% in the entire market, on account of the expanding elderly population and the rise in hereditary predispositions.
With respect to treatment & diagnosis, the market caters to treatment as well as diagnosis. The treatment-wise categories are nutritional support, intravenous fluid, endoscopic retrograde cholangiopancreatography (ERCP), analgesics, and more. The diagnosis-based segments include laboratory tests and imaging tests.
Hospitals & clinics and more are the key end-users in the worldwide industry.
Regional Analysis –
The market segmentation, with regard to region, includes Europe, Asia Pacific or APAC, MEA or Middle East & Africa and the Americas.
As of 2018, the American market owned a share of 41.05% and can proceed to take the lead during the review timeline. Some of the key growth inducers are the rising cases of gall stones and the notable spike in alcohol consumption among people. High availability of quality and superior healthcare facilities across the US and Canada and the rapidly burgeoning geriatric populace also bolster the market demand in the region. The sharp rise in cases of acute pancreatitis in the region has promoted a higher demand for more effective and advanced diagnostic tests as well as treatment options, for which several players are giving intense efforts to gain the upper hand in the market.
The European market predominantly benefits from the escalating number of chronic disorder cases, rampant demand for disease specific treatment and the rising uptake of newer and innovative technologies in the healthcare industry. The existence of a robust and well-developed healthcare infrastructure paired with the soaring awareness level among patients with regard to pancreatitis could lead the European market to greater heights in the following years.
The extensive market growth in APAC is the result of the rising prominence of pancreatic cancer and the soaring need for effective diagnostic tests as well as treatment. Considering the aggravating scenario in the region, a number of non-profit organizations and government agencies are taking up initiatives to boost the awareness level with regard to acute pancreatitis. Technological developments with respect to treatment and diagnostics are giving rise to efficient solutions, which could translate into substantial gains for the regional market in the years to come.
Renowned Contenders –
Acute pancreatitis companies include CalciMedica, SCM Lifescience, Samsung Bioepis, GNT Pharma Co., Baxter International Inc., Braun Melsungen AG, General Electric Company, Medtronic, Boston Scientific Corporation, and Fresenius Kabi USA.
For more information visit at MarketResearchFuture
